Combining kinomics, longitudinal drug screening with ex vivo, in vivo TME, and patient-derived xenograft (PDX) models, we identified a major kinase network involving PI3K-AKT-mTOR/integrin β1-integrin-linked kinase (ILK) as a central hub for TME–lymphoma interactions mediating IR. Here, MTOR is linked to lymphoma.